» Articles » PMID: 31369099

Identifying Critically Important Vascular Access Outcomes for Trials in Haemodialysis: an International Survey with Patients, Caregivers and Health Professionals

Abstract

Background: Vascular access outcomes reported across haemodialysis (HD) trials are numerous, heterogeneous and not always relevant to patients and clinicians. This study aimed to identify critically important vascular access outcomes.

Method: Outcomes derived from a systematic review, multi-disciplinary expert panel and patient input were included in a multilanguage online survey. Participants rated the absolute importance of outcomes using a 9-point Likert scale (7-9 being critically important). The relative importance was determined by a best-worst scale using multinomial logistic regression. Open text responses were analysed thematically.

Results: The survey was completed by 873 participants [224 (26%) patients/caregivers and 649 (74%) health professionals] from 58 countries. Vascular access function was considered the most important outcome (mean score 7.8 for patients and caregivers/8.5 for health professionals, with 85%/95% rating it critically important, and top ranked on best-worst scale), followed by infection (mean 7.4/8.2, 79%/92% rating it critically important, second rank on best-worst scale). Health professionals rated all outcomes of equal or higher importance than patients/caregivers, except for aneurysms. We identified six themes: necessity for HD, applicability across vascular access types, frequency and severity of debilitation, minimizing the risk of hospitalization and death, optimizing technical competence and adherence to best practice and direct impact on appearance and lifestyle.

Conclusions: Vascular access function was the most critically important outcome among patients/caregivers and health professionals. Consistent reporting of this outcome across trials in HD will strengthen their value in supporting vascular access practice and shared decision making in patients requiring HD.

Citing Articles

Vascular Access for Home Hemodialysis: A Perspective on Tunneled Central Venous Catheters at Home.

Aragon M, El Shamy O, Zheng S, Chertow G, Glickman J, Weinhandl E Kidney Med. 2025; 7(1):100916.

PMID: 39803418 PMC: 11721530. DOI: 10.1016/j.xkme.2024.100916.


Paclitaxel- or sirolimus-coated balloons used for ArterioVEnous fistulas-2 (PAVE-2): study protocol for a randomised controlled trial to determine the efficacy of paclitaxel- or sirolimus-coated balloons in arteriovenous fistulas used for....

Karunanithy N, Norton S, Calder F, Das N, Dooley N, Hakobyan L Trials. 2024; 25(1):734.

PMID: 39482722 PMC: 11529252. DOI: 10.1186/s13063-024-08502-1.


Analysis of risk factors for late arteriovenous fistula failure and patency rates after angioplasty in hemodialysis patients: a retrospective cohort study.

Long J, Chen H, Huang Q, Chen X, Ellis R, Zanoli L Transl Androl Urol. 2024; 13(2):209-217.

PMID: 38481870 PMC: 10932638. DOI: 10.21037/tau-23-431.


Rethinking an effective AV fistula-graft screening program. An "A B C".

Lomonte C, Corciulo S, Cortese D, Libutti P, Montinaro V, Gesualdo L J Nephrol. 2023; 36(7):1861-1865.

PMID: 37458910 DOI: 10.1007/s40620-023-01669-x.


Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID) : A multi-center, multinational validation study to assess the accuracy and feasibility of measuring vascular access function in clinical....

Viecelli A, Teixeira-Pinto A, Valks A, Baer R, Cherian R, Cippa P BMC Nephrol. 2022; 23(1):372.

PMID: 36402958 PMC: 9675211. DOI: 10.1186/s12882-022-02987-1.